Diagnostic Potential of Two Novel Biomarkers for Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis

Background: Currently, no tests can definitively diagnose and distinguish neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS). Methods: Initially, cerebrospinal fluid (CSF) proteomics were employed to uncover the novel biomarkers that differentiate NMOSD from MS into cohorts...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ting, Shi, Yijun, Zheng, Guanghui, Zhang, Guojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178292/
https://www.ncbi.nlm.nih.gov/pubmed/37174963
http://dx.doi.org/10.3390/diagnostics13091572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178292/
https://www.ncbi.nlm.nih.gov/pubmed/37174963
http://dx.doi.org/10.3390/diagnostics13091572

Ejemplares similares